Grants for Private institutions of higher education - Federal

This funding opportunity supports projects that promote inclusive economic growth and human development in Equatorial Guinea, encouraging collaboration between local and U.S. organizations, individuals, and educational institutions.

This funding opportunity supports alumni of U.S. government-sponsored exchange programs in Lebanon to implement innovative projects that promote good governance, social cohesion, and cultural heritage while encouraging diversity and inclusion.

This grant provides funding to U.S. colleges and universities to develop training programs that educate Georgian importers and processors about U.S. poultry products, with the goal of increasing exports to Georgia and surrounding regions.

This funding opportunity provides financial support for large-scale marine debris removal projects that enhance the resilience of coastal and marine environments, benefiting local communities and economies.

This grant provides funding for innovative research aimed at developing new methods and tools to protect military personnel from diseases transmitted by insects, while also improving pest control strategies for bed bugs and filth flies.

Orthopaedic injuries have a profound impact on military readiness and return to work/activity/duty. In the military, extremity battle wounds comprise approximately 50% of injuries reported in the Department of Defense Trauma Registry. Additionally, orthopaedic injuries and conditions that occur outside of combat (e.g., during training, leisure activities, resultant from old injuries) present one of the greatest threats to the readiness of our Service Members and military. Early stabilization, treatment, and rehabilitation of orthopaedic injuries in both civilian and military populations have led to better outcomes, particularly in the prevention of secondary complications and in minimizing morbidity. Availability of orthopaedic care and treatment as early as possible, or as close to the point of injury as possible, also minimizes limb loss and affects military readiness.Although the PRORP is interested in supporting military-focused research, research supported by the PRORP is expected to also apply to all individuals who have sustained a major orthopaedic injury.With the initiation of the Arthritis Research Program, the FY24 PRORP may not fund arthritis research; however, research that addresses conditions or health abnormalities related to arthritis is permitted provided the proposed research addresses the selected Focus Area.The PRORP CTRA is intended to support high-impact and/or emerging clinical research that may not be ready for a full-scale randomized controlled clinical trial. Projects should demonstrate potential to impact the standard of care, both immediate and long-term, as well as contribute to evidence-based guidelines for the evaluation and care of military, Veterans, and all patients with orthopaedic injuries. One goal of the FY24 PRORP CTRA is to translate current and emerging techniques and interventions into the clinical space to better serve military and non-military patients. A holistic approach that takes into account the health, functional abilities, and quality of life of individuals who have sustained an orthopaedic injury should be considered. Another goal is to identify the most effective diagnosis, treatment, rehabilitation, and prevention options available to support critical decision-making for patients, clinicians, other caregivers, and policymakers.The FY24 PRORP CTRA differs from the FY24 PRORP Clinical Trial Award (CTA) in that the CTRA allows for clinical research projects that may or may not include a clinical trial, whereas the CTA is restricted to clinical trials only.Funding from this award mechanism must support clinical research and may not be used for animal research.Clinical research encompasses research with patient samples, data, and interaction with patients that may or may not be considered a clinical trial. Clinical research is observational in nature and includes: (1) Research that does not seek to evaluate the effects of interventions. Research conducted with human subjects (or on material of human origin such as data, tissues, specimens, and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects but does not seek to assess the effects of an intervention, qualifies as clinical research. Patient-oriented research may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to study the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human tissues that cannot be linked to a living individual. Note: Studies that meet the requirements for exemption under 46.104(d)(4) of the Common Rule are not considered clinical research as defined by the CDMRP. Exemption category 4 refers to secondary research for which consent is not required.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/Human%20Subjects%20Resource%20Document_DEC2022.pdf.Proposed studies submitted to the CTRA may be interventional and may involve some retrospective data analysis. Note that purely retrospective or database-related research is not allowed under this funding opportunity. Small pilot clinical trials with human subjects are allowable.Key aspects of the PRORP CTRA mechanism: Preliminary Data Are Required: Inclusion of preliminary data relevant to the proposed clinical research is required. Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical research appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Intervention Availability: The application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study. Statistical Analysis and Data Management Plans: The application should include a clearly articulated statistical analysis plan, a power analysis reflecting sample size projections that will answer the objectives of the study, and a data management plan that includes use of an appropriate database to safeguard and maintain the integrity of the data. If proposing a clinical trial that requires oversight by a Regulatory Agency, the trial must use a 21 CFR 11-compliant database and appropriate data standards.For the purposes of this funding opportunity, Regulatory Agency refers to the U.S. Food and Drug Administration (FDA) or any relevant international regulatory agency unless otherwise noted.If the proposed clinical research involves the use of a drug that has not been approved by the relevant Regulatory Agency for the country where the research will be conducted, then submission of an Investigational New Drug (IND) application, or equivalent, that meets all requirements under 21 CFR 312 may be required. It is the responsibility of the applicant to provide evidence from the IRB of record or the relevant Regulatory Agency if an IND, or equivalent, is not required. If an IND, or equivalent, is required, the regulatory application must be submitted to the relevant Regulatory Agency within 12 months of the CTRA award start date. The IND, or equivalent, should be specific for the product and indication to be tested in the proposed clinical trial. For more information on IND applications specifically, the FDA has provided guidance at https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application.If the investigational product is a device, then submission of an Investigational Device Exemption (IDE), or equivalent, application that meets all requirements under 21 CFR 812 may be required. It is the responsibility of the applicant to provide evidence if an IDE, or equivalent, is not required. If an IDE, or equivalent, is required, the IDE application, or equivalent, must be submitted to the relevant Regulatory Agency within 12 months of the CTRA award start date. The IDE, or equivalent, should be specific for the device and indication to be tested in the proposed clinical trial.Womens Health: The CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health. Applications proposing research that solely address womens health may also consider the FY24 PRORP WHRA mechanism, Funding Opportunity Number HT942524PRORPWHRA.Use of Department of Defense (DOD) or VA Resources: If the proposed research involves access to DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated total costs budgeted for the entire period of performance for an FY24 PRORP CTRA should not exceed $1.5M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $6.0M to fund approximately four CTRA applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity provides up to $500,000 for researchers to conduct innovative studies that inform tobacco product regulation and public health, with a focus on understanding tobacco use, its health effects, and addiction.

The "U.S. Embassy Oslo Public Diplomacy Section (PDS) Annual Program Statement" grant aims to fund projects by eligible organizations and individuals that promote U.S.-Norway relations, with a focus on areas such as global security, Arctic issues, climate change, media influence, diversity, cultural heritage, shared values, U.S. higher education, and cross-border collaborations.

This program provides funding to U.S. colleges and universities to foster collaborative research partnerships with industry and government, focusing on innovative solutions to critical national challenges while developing a skilled workforce in science and engineering.

This grant provides funding to various government entities, educational institutions, and nonprofit organizations in New Mexico to manage and control invasive plant species on public lands, protecting native ecosystems and promoting community engagement.

This funding opportunity provides financial support to organizations working to strengthen export controls and compliance measures against the Chinese Communist Party's efforts to acquire advanced technologies for military and economic purposes.

The Fiscal Year 2025 Air Force Young Investigator Research Program (YIP) intends to support individual early in career scientists and engineers who have received Ph.D. or equivalent degrees by 01 April 2017 or later showing exceptional ability and promise for conducting basic research. The program objective is to foster creative basic research in science and engineering; enhance early career development of outstanding young investigators; and increase opportunities for the young investigator to recognize the Air Force and Space Force mission and related challenges in science and engineering.Individual awards are made to U.S. institutions of higher education, industrial laboratories, for- profit, or non-profit research organizations where the principal investigator (PI) is employed on a full-time basis and holds a regular, non-contractor position. A YIP PI must be a U.S. citizen, national, or permanent resident. Researchers working at a Federally Funded Research and Development Center, or a Department of Defense (DoD) Laboratory are not eligible for this competition.YIP awards are funded up to $150,000 per year for three years, for a total of $450,000. No single year may exceed $150,000. Please review the remainder of this announcement for additional information.Under this competition, an anticipated thirty-seven (37) traditionally funded YIPs and two YIPs funded in partnership with the Laboratory for Physical Sciences (LPS) in the Quantum Information Sciences research discipline may be awarded. There may be potential for an additional 37 YIPs funded from other AFOSR research funding. All actions are based on the availability of funds.

This funding opportunity provides financial support to organizations working to review wrongful convictions and improve the integrity of the criminal justice system, particularly in underserved rural areas.

This funding opportunity provides financial support for research consortia focused on improving the diagnosis and treatment of rare diseases through collaborative, patient-centered clinical studies involving multiple institutions and patient advocacy groups.

This funding opportunity is designed to support a variety of organizations, particularly local Mexican entities, in implementing projects that align with USAID's development goals in Mexico over a period of up to five years.

Funding Opportunity PurposeThe full-scale Diversity Centers for Genome Research (DCGR) program aims to establish Genomic Research Centers at Minority Serving Institutions (MSIs) as defined in Part 2, section III of the FOA. The MSIs must have a mission to serve historically underrepresented populations in biomedical research that award doctorate degrees in the health professions or the sciences related to health, and have received an average of less than $50 million per year in NIH support and less than $25 million per year of R01 total cost of NIH support for the past three fiscal years. The purpose of this FOA is to call for applications for UG3/UH3 cooperative agreements to support the development and planning for a multi-investigator, interdisciplinary team to develop administrative, genomic workforce development and community engagement cores and 2-3 interrelated, innovative genomic research projects that address one or more critical issues in genomics including: genomic technology and methods development; genome structure; genome function; genomics of disease; use and impact of genomic information in clinical care; genomic data science and computational genomics, ethical, legal, and social implications of genomic research (ELSI); and/or genomics and health equity. The outcome of the development and feasibility studies will be fully developed plans to carry out all activities of a full-scale Diversity Center for Genome Research. Along with its scientific goals, the DCGR should expand the pool of diverse genomic scientists, clinician scientists, and researchers who can perform innovative genomics research by providing didactic, practicum and research activities and experiences that are aligned with the research projects.

This funding opportunity provides financial support for research projects that enhance understanding of climate variability in the eastern equatorial Pacific, targeting institutions, non-profits, and governments involved in climate science and modeling.

With this solicitation, BJA seeks to support comprehensive community-based approaches to addressing hate crimes that promote community awareness and preparedness, increase victim reporting, and improve responses to hate crimes. The program is also designed to develop community-informed models for preventing and responding to hate speech and incidents, as well as facilitating reconciliation and community healing.

This grant provides funding to support the development of emerging climate scientists and innovators from diverse backgrounds at research institutions, focusing on professional growth and community engagement to address climate change challenges.

This grant provides funding to various organizations, including government agencies and nonprofits, to help farmers in the Western Lake Erie Basin adopt better nutrient management practices that reduce harmful agricultural runoff and improve water quality.